NCT01327235

Endostar and/or Cisplatin for Treatment of Malignant Pleural Effusion or Ascites

A Randomized Controlled Multicenter Trial of Endostar and/or Cisplatin in Patients With Malignant Pleural Effusion or Ascites

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 336 (actual)
• Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to compare the efficacy of Endostar/cisplatin with cisplatin alone or Endostar alone in patients with malignant pleural effusion or ascites.

Conditions

• Malignant Pleural Effusion
• Malignant Ascites

Interventions

Type	Name	Description
DRUG	Endostar	intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
DRUG	Cisplatin	cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles

Timeline

• Start date: 2011-03-01
• Primary completion: 2014-04-01
• Completion: 2014-07-01
• First posted: 2011-04-01
• Last updated: 2014-08-01

Locations

3 sites across 1 country: China